ClinicalTrials.gg
CompletedNCT02559622CARIMAUpdated Jul 13, 2017Results posted

Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab

A Phase 3 interventional study of Secukinumab and Placebo in Psoriasis, sponsored by Novartis Pharmaceuticals. Completed at 23 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-13.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
151
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 54 studies testing secukinumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. secukinumab · Psoriasis.

Enrollment
23rd of 54
151 · median 124
Started
2014
with 2 others
Phase 3
24 of 54
none open now
Registered
29th of 54
by date
Lead sponsor
37 of 54
Novartis Pharmaceuticals

Among the 54 studies testing secukinumab in Psoriasis, this one is the 23rd largest by enrollment, is one of 3 that started in 2014, is one of 24 in phase 3, and was the 29th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 54 studies testing secukinumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About secukinumab

secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing secukinumab in Psoriasis, or all of them as a file.
02

Study summary

The purpose of this study was to explore the effect of treatment with 300 mg or with 150 mg secukinumab (administered weekly for 4 weeks followed by four-weekly administration) on endothelial dysfunction and arterial stiffness after 12 weeks and for up to 52 weeks in subjects with chronic plaque-type psoriasis. Furthermore soluble biomarkers were assessed to evaluate the influence of secukinumab on cardiovascular risk. Magnetic resonance imaging (MRI) was performed in a sub-population to assess the treatment effect on arterial vessel wall morphometry in atherosclerosis prone vascular beds.

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Chronic moderate to severe plaque type psoriasis for at least 6 months prior to randomization with a Psoriasis Area and Severity Index (PASI) score ≥ 10 at randomization.
  • Inadequate response, intolerance or to cyclosporine, methotrexate and psoralen plus ultraviolet A light treatment (PUVA) as documented in the patient's medical history or reported by the patient or determined by the investigator at screening. Relative contraindications such as interference of patient's lifestyle with the treatment are accepted.

Key Exclusion Criteria:

  • Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and guttata psoriasis) at screening or randomization.
  • Ongoing use of prohibited psoriasis and non-psoriasis treatments.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
151 participants (actual)

Study arms

  • Experimental
    300 mg secukinumab

    300 mg secukinumab every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection)

    Drug: Secukinumab

  • Experimental
    150 mg secukinumab

    150 mg secukinumab every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection)

    Drug: Secukinumab

  • Other
    Placebo followed by 300 mg secukinumab

    Placebo until week 12 followed by 300 mg secukinumab every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection)

    Other: Placebo

  • Other
    Placebo followed by 150 mg secukinumab

    Placebo until week 12 followed by 150 mg secukinumab every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection)

    Other: Placebo

Interventions

  • 300 mg secukinumab

    Also known as: AIN457

  • OtherPlacebo

    Placebo followed by 300 mg secukinumab

  • OtherPlacebo

    Placebo followed by 150 mg secukinumab

  • 150 mg secukinumab

    Also known as: AIN457

06

What researchers measure

Primary outcomes

  1. Flow Mediated Dilation (FMD) at Week 12 Followed by Secukinumab 300 mg vs Pooled Placebo Treatment

    Flow Mediated Dilation (FMD) is non-invasive method evaluated by Doppler Ultrasound test, to assess endothelial function. FMD was calculated as the percent maximal deviation from the baseline arterial diameter (D):FMD = 100\*\[(D maximum - D baseline) / D baseline\]. Here, arterial diameter (brachial artery) was measured at rest (1 minute), during inflation of the distal cuff to 100 millimeter of mercury (mmHg) for 4.5 minutes and for 4.5 minutes following deflation.

    Time frame: Week 12

Secondary outcomes

  1. Change From Baseline in Flow Mediated Dilation (FMD) at Week 4, 12, 24 and 52

    FMD is non-invasive method evaluated by Doppler Ultrasound test, to assess endothelial function. FMD was calculated as the percent maximal deviation from the baseline arterial diameter (D):FMD = 100\*\[(D maximum - D baseline) / D baseline\]. Here, arterial diameter (brachial artery) was measured at rest (1 minute), during inflation of the distal cuff to 100 mmHg for 4.5 minutes and for 4.5 minutes following deflation. A positive change in FMD constitutes an improvement in endothelial function.

    Time frame: Baseline, Week 4, 12, 24 and 52

  2. Change From Baseline in Aortic Augmentation Index at Heart Rate of 75 (AIx-75) at Week 4, 12, 24 and 52

    Pulse wave analysis was performed on the central aortic pressure waveform as derived by SphygmoCor XCEL from the brachial pressure waveform recorded in a partially-inflated blood pressure cuff around the upper arm. The waveform derivation employs a validated generalized transfer function to convert a brachial waveform to a central waveform and has been shown to produce measurement results corresponding to measurements using intra-arterial pressure catheters. The augmentation index is derived from the waveform by determining the percentage of the central pulse pressure during systole due to wave reflection. AIx was heart-rate corrected to calculate the AIx at a heart rate of 75 bpm, i.e. AIx-75.

    Time frame: Baseline, Week 4, 12, 24 and 52

  3. Change From Baseline in Pulse Wave Velocity (PWV) at Week 4, 12, 24 and 52

    Regional arterial pulse wave velocity (PWV) was directly related to arterial stiffness and was defined as the time it takes for the blood pressure wave to travel from a proximal site to a distal site (relative to the heart) divided by the distance (PWV = ∆distance/∆time \[m/s\]). The foot of the arterial pulse wave was being recorded by using the SphygmoCor XCEL device. XCEL simultaneously measures the pressure waveform at the femoral site (using a partially inflated custom blood pressure cuff) and the carotid site (using hand-held applanation tonometry). The foot-to-foot time between the two pressure waveforms was the time interval used in the PWV calculation.

    Time frame: Baseline, Week 4, 12, 24 and 52

  4. Change From Baseline in Average Wall Area Assessed as a Measure of Total Plaque Burden at Week 12

    Magnetic resonance imaging (MRI) was used to evaluate vessel wall morphometry to determine plaque burden. As a measure of plaque burden, average wall area was computed by subtracting vessel lumen area from total vessel area. Exploratory 3.0 Tesla MRI technique was applied to assess structure and function of the carotid and the aorta. A 2D axial dark blood T1, T2, proton density weighted spin echo based images and time of flight images were acquired from the bilateral carotid arteries as well as the descending aorta.

    Time frame: Baseline, Week 12

  5. Change From Baseline in Average Wall Area Assessed as a Measure of Total Plaque Burden at Week 52

    Magnetic resonance imaging (MRI) was used to evaluate vessel wall morphometry to determine plaque burden. As a measure of plaque burden, average wall area was computed by subtracting vessel lumen area from total vessel area. Exploratory 3.0 Tesla MRI technique was applied to assess structure and function of the carotid and the aorta. A 2D axial dark blood T1, T2, proton density weighted spin echo based images and time of flight images were acquired from the bilateral carotid arteries as well as the descending aorta.

    Time frame: Baseline, Week 52

  6. Change From Baseline in High Sensitivity C-reactive Protein (hsCRP) at Week 4, 12, 24 and 52

    High sensitivity C-reactive protein (hsCRP), a soluble biomarker of systemic inflammation was determined in fasting blood samples to evaluate the effect of secukinumab on systemic inflammation.

    Time frame: Baseline, Week 4, 12, 24 and 52

  7. Change From Baseline in S-100 Protein B (Total) at Week 4, 12, 24 and 52

    S100 calcium-binding protein B (S100B-protein), a soluble biomarker of systemic inflammation was determined in fasting blood samples to evaluate the effect of secukinumab on systemic inflammation.

    Time frame: Baseline, Week 4, 12, 24 and 52

  8. Change From Baseline in Chemokine (C-c Motif) Ligand 5 (CCL5), Monocyte Chemoattractant Protein 1 (MCP-1) and Macrophage Inflammatory Proteins (MIP) 1 Alpha and 1 Beta at Week 4, 12, 24 and 52

    Chemokine (c-c motif) ligand 5 (CCL5), Monocyte chemoattractant protein 1 (MCP-1) and Macrophage inflammatory proteins (MIP) 1 alpha (1A) and 1 beta (1B), soluble biomarkers of systemic inflammation were determined in fasting blood samples to evaluate the effect of secukinumab on systemic inflammation.

    Time frame: Baseline, Week 4, 12, 24 and 52

  9. Change From Baseline in Fasting Plasma Glucose (FPG) at Week 4, 12, 24 and 52

    Fasting plasma glucose (FPG), a soluble biomarker of Dysglycemia was determined in fasting blood samples to evaluate the effect of secukinumab on systemic inflammation.

    Time frame: Baseline, Week 4, 12, 24 and 52

  10. Change From Baseline in Fasting Insulin at Week 4, 12, 24 and 52

    Fasting Insulin, a soluble biomarker of Dysglycemia was determined in fasting blood samples to evaluate the effect of secukinumab on Dysglycemia.

    Time frame: Baseline, Week 4, 12, 24 and 52

  11. Change From Baseline in Homeostatic Model Assessment (HOMA) Beta-cell Function at Week 4, 12, 24 and 52

    Homeostatic Model Assessment (HOMA) beta-cell function, a soluble biomarker of Dysglycemia was determined in fasting blood samples to evaluate the effect of secukinumab on Dysglycemia.

    Time frame: Baseline, Week 4, 12, 24 and 52

  12. Change From Baseline in Homeostatic Model Assessment (HOMA) Insulin Resistance at Week 4, 12, 24 and 52

    HOMA insulin resistance, a soluble biomarker of Dysglycemia was determined in fasting blood samples to evaluate the effect of secukinumab on Dysglycemia.

    Time frame: Baseline, Week 4, 12, 24 and 52

  13. Change From Baseline in Hemoglobin A1c (Glycated Hemoglobin) at Week 4, 12, 24 and 52

    Hemoglobin A1c (glycated hemoglobin), a soluble biomarker of Dysglycemia was determined in fasting blood samples to evaluate the effect of secukinumab on Dysglycemia.

    Time frame: Baseline, Week 4, 12, 24 and 52

  14. Change From Baseline in Sex Hormone-binding Globulin (SHBG) at Week 4, 12, 24 and 52

    Sex hormone-binding globulin (SHBG), a soluble biomarker of Dysglycemia was determined in fasting blood samples to evaluate the effect of secukinumab on Dysglycemia.

    Time frame: Baseline, Week 4, 12, 24 and 52

  15. Change From Baseline in Triglycerides, Total Cholesterol, Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), Apolipoprotein A-1 (ApoA-1) and Apolipoprotein B (ApoB) at Week 4, 12, 24 and 52

    Triglycerides, Total cholesterol, Low density lipoprotein (LDL), High density lipoprotein (HDL), Apolipoprotein A-1 (ApoA-1) and Apolipoprotein B (ApoB), soluble biomarkers of impaired lipid metabolism were determined in fasting blood samples to evaluate the effect of secukinumab on impaired lipid metabolism.

    Time frame: Baseline, Week 4, 12, 24 and 52

  16. Change From Baseline in Adiponectin at Week 4, 12, 24 and 52

    Adiponectin, a soluble biomarker of impaired lipid metabolism was determined in fasting blood samples to evaluate the effect of secukinumab on systemic inflammation.

    Time frame: Baseline, Week 4, 12, 24 and 52

  17. Change From Baseline in Leptin at Week 4, 12, 24 and 52

    Leptin, a soluble biomarker of impaired lipid metabolism was determined in fasting blood samples to evaluate the effect of secukinumab on systemic inflammation.

    Time frame: Baseline, Week 4, 12, 24 and 52

07

Results

Posted Jul 13, 2017

Participant flow

The study was conducted at 23 centers in Germany.

Participant flow — Overall Study
MilestoneSecukinumab 300 mgSecukinumab 150 mgPlacebo Followed by 300 mg SecukinumabPlacebo Followed by 150 mg Secukinumab
Started48542623
Completed47492420
Not completed1523
Withdrew: Progressive disease0100
Withdrew: Adverse event0222
Withdrew: Patient/guardian decision1201

Outcome measures

PrimaryFlow Mediated Dilation (FMD) at Week 12 Followed by Secukinumab 300 mg vs Pooled Placebo Treatment

Flow Mediated Dilation (FMD) is non-invasive method evaluated by Doppler Ultrasound test, to assess endothelial function. FMD was calculated as the percent maximal deviation from the baseline arterial diameter (D):FMD = 100\*\[(D maximum - D baseline) / D baseline\]. Here, arterial diameter (brachial artery) was measured at rest (1 minute), during inflation of the distal cuff to 100 millimeter of mercury (mmHg) for 4.5 minutes and for 4.5 minutes following deflation.

Time frame:
Week 12
Reported as:
Mean · Percentage maximal increase in diameter
Flow Mediated Dilation (FMD) at Week 12 Followed by Secukinumab 300 mg vs Pooled Placebo Treatment
Percentage maximal increase in diameterSecukinumab 300 mgPlacebo (Pooled)
Flow Mediated Dilation (FMD) at Week 12 Followed by Secukinumab 300 mg vs Pooled Placebo Treatment5.23 ± 5.303.65 ± 4.07
Statistical analysis
  • Secukinumab 300 mg vs Placebo (Pooled) · ANCOVA · p = 0.2230 · Least square (ls) mean difference: 1.17 · 95% CI -0.72 to 3.06
SecondaryChange From Baseline in Flow Mediated Dilation (FMD) at Week 4, 12, 24 and 52

FMD is non-invasive method evaluated by Doppler Ultrasound test, to assess endothelial function. FMD was calculated as the percent maximal deviation from the baseline arterial diameter (D):FMD = 100\*\[(D maximum - D baseline) / D baseline\]. Here, arterial diameter (brachial artery) was measured at rest (1 minute), during inflation of the distal cuff to 100 mmHg for 4.5 minutes and for 4.5 minutes following deflation. A positive change in FMD constitutes an improvement in endothelial function.

Time frame:
Baseline, Week 4, 12, 24 and 52
Reported as:
Mean · Percentage change in FMD
Change From Baseline in Flow Mediated Dilation (FMD) at Week 4, 12, 24 and 52
Percentage change in FMDSecukinumab 300 mgSecukinumab 150 mgPlacebo Followed by 300 mg SecukinumabPlacebo Followed by 150 mg Secukinumab
Week 4-0.7 (-1.9 to 0.5)-0.9 (-2.4 to 0.7)0.7 (-1.0 to 2.5)1.4 (-0.8 to 3.6)
Week 120.5 (-1.1 to 2.1)0.1 (-1.2 to 1.5)-0.1 (-2.7 to 2.4)0.1 (-2.1 to 2.3)
Week 24-0.8 (-1.9 to 0.3)1.0 (-0.4 to 2.4)-0.0 (-2.6 to 2.6)0.9 (-1.0 to 2.9)
Week 522.1 (0.8 to 3.3)2.1 (0.7 to 3.4)2.2 (-0.5 to 4.9)1.2 (-1.0 to 3.5)
SecondaryChange From Baseline in Aortic Augmentation Index at Heart Rate of 75 (AIx-75) at Week 4, 12, 24 and 52

Pulse wave analysis was performed on the central aortic pressure waveform as derived by SphygmoCor XCEL from the brachial pressure waveform recorded in a partially-inflated blood pressure cuff around the upper arm. The waveform derivation employs a validated generalized transfer function to convert a brachial waveform to a central waveform and has been shown to produce measurement results corresponding to measurements using intra-arterial pressure catheters. The augmentation index is derived from the waveform by determining the percentage of the central pulse pressure during systole due to wave reflection. AIx was heart-rate corrected to calculate the AIx at a heart rate of 75 bpm, i.e. AIx-75.

Time frame:
Baseline, Week 4, 12, 24 and 52
Reported as:
Mean · Percentage change in Alx-75
Change From Baseline in Aortic Augmentation Index at Heart Rate of 75 (AIx-75) at Week 4, 12, 24 and 52
Percentage change in Alx-75Secukinumab 300 mgSecukinumab 150 mgPlacebo Followed by 300 mg SecukinumabPlacebo Followed by 150 mg Secukinumab
Week 40.0 (-2.8 to 2.9)0.3 (-2.0 to 2.7)1.1 (-1.7 to 3.8)-0.1 (-3.0 to 2.9)
Week 12-0.5 (-3.0 to 2.1)1.0 (-1.7 to 3.8)-1.1 (-5.4 to 3.3)-0.1 (-3.4 to 3.2)
Week 243.0 (0.3 to 5.6)1.8 (-0.6 to 4.3)1.3 (-2.7 to 5.3)0.7 (-2.7 to 4.1)
Week 521.3 (-1.5 to 4.2)-0.1 (-2.8 to 2.7)-1.4 (-5.8 to 2.9)-0.9 (-4.2 to 2.5)
SecondaryChange From Baseline in Pulse Wave Velocity (PWV) at Week 4, 12, 24 and 52

Regional arterial pulse wave velocity (PWV) was directly related to arterial stiffness and was defined as the time it takes for the blood pressure wave to travel from a proximal site to a distal site (relative to the heart) divided by the distance (PWV = ∆distance/∆time \[m/s\]). The foot of the arterial pulse wave was being recorded by using the SphygmoCor XCEL device. XCEL simultaneously measures the pressure waveform at the femoral site (using a partially inflated custom blood pressure cuff) and the carotid site (using hand-held applanation tonometry). The foot-to-foot time between the two pressure waveforms was the time interval used in the PWV calculation.

Time frame:
Baseline, Week 4, 12, 24 and 52
Reported as:
Mean · meters per second (m/s)
Change From Baseline in Pulse Wave Velocity (PWV) at Week 4, 12, 24 and 52
meters per second (m/s)Secukinumab 300 mgSecukinumab 150 mgPlacebo Followed by 300 mg SecukinumabPlacebo Followed by 150 mg Secukinumab
Week 4 (n = 192, 262, 133, 104)0.0 (-0.2 to 0.2)-0.2 (-0.3 to 0.0)0 (-0.1 to 0.2)-0.2 (-0.5 to 0.2)
Week 12 (n = 214, 255, 116, 133)0.4 (0.2 to 0.6)0.1 (-0.1 to 0.2)0.1 (-0.2 to 0.4)0.4 (0.1 to 0.7)
Week 24 (n = 205, 255, 100, 100)0.2 (-0.1 to 0.5)0.0 (-0.2 to 0.1)0.2 (0.1 to 0.4)-0.1 (-0.5 to 0.2)
Week 52 (n = 191, 228, 115, 101)-0.1 (-0.3 to 0.0)0.2 (-0.1 to 0.5)0.1 (-0.2 to 0.4)-0.2 (-0.6 to 0.2)
SecondaryChange From Baseline in Average Wall Area Assessed as a Measure of Total Plaque Burden at Week 12

Magnetic resonance imaging (MRI) was used to evaluate vessel wall morphometry to determine plaque burden. As a measure of plaque burden, average wall area was computed by subtracting vessel lumen area from total vessel area. Exploratory 3.0 Tesla MRI technique was applied to assess structure and function of the carotid and the aorta. A 2D axial dark blood T1, T2, proton density weighted spin echo based images and time of flight images were acquired from the bilateral carotid arteries as well as the descending aorta.

Time frame:
Baseline, Week 12
Reported as:
Mean · millimeter square (mm^2)
Change From Baseline in Average Wall Area Assessed as a Measure of Total Plaque Burden at Week 12
millimeter square (mm^2)Secukinumab 300 mgSecukinumab 150 mgPlacebo Followed by 300 mg SecukinumabPlacebo Followed by 150 mg Secukinumab
Ascending thoracic aorta15.35 (-8.23 to 38.92)5.91 (-13.09 to 24.91)9.92 (-58.24 to 78.08)6.45 (-9.26 to 22.15)
Descending thoracic aorta2.69 (-14.18 to 19.56)-2.94 (-13.44 to 7.57)-4.04 (-29.61 to 21.53)3.16 (-13.73 to 20.05)
Carotid bifurcation left0.52 (-2.72 to 3.77)-1.08 (-3.85 to 1.69)3.63 (-7.82 to 15.08)1.12 (-2.04 to 4.28)
Carotid bifurcation right-0.77 (-3.60 to 2.06)1.75 (-0.71 to 4.21)-1.26 (-7.64 to 5.12)-1.07 (-4.24 to 2.10)
Common carotid left0.17 (-1.64 to 1.99)1.12 (-1.80 to 4.03)0.69 (-5.21 to 6.59)0.12 (-1.91 to 2.15)
Common carotid right-0.12 (-2.17 to 1.92)0.30 (-2.76 to 3.36)-0.38 (-6.56 to 5.80)-0.14 (-1.60 to 1.32)
Internal carotid left3.79 (-0.19 to 7.78)2.09 (-0.57 to 4.75)2.59 (-0.58 to 5.77)-1.74 (-4.55 to 1.08)
Internal carotid right-0.69 (-1.90 to 0.51)0.17 (-1.96 to 2.30)0.68 (-3.97 to 5.33)-1.37 (-4.37 to 1.62)
Descending abdominal aorta8.71 (-6.33 to 23.76)-3.79 (-21.90 to 14.32)4.56 (-52.64 to 61.77)-0.58 (-15.51 to 14.35)
SecondaryChange From Baseline in Average Wall Area Assessed as a Measure of Total Plaque Burden at Week 52

Magnetic resonance imaging (MRI) was used to evaluate vessel wall morphometry to determine plaque burden. As a measure of plaque burden, average wall area was computed by subtracting vessel lumen area from total vessel area. Exploratory 3.0 Tesla MRI technique was applied to assess structure and function of the carotid and the aorta. A 2D axial dark blood T1, T2, proton density weighted spin echo based images and time of flight images were acquired from the bilateral carotid arteries as well as the descending aorta.

Time frame:
Baseline, Week 52
Reported as:
Mean · mm^2
Change From Baseline in Average Wall Area Assessed as a Measure of Total Plaque Burden at Week 52
mm^2Secukinumab 300 mgSecukinumab 150 mgPlacebo Followed by 300 mg SecukinumabPlacebo Followed by 150 mg Secukinumab
Ascending thoracic aorta14.42 (-14.93 to 43.76)3.19 (-17.17 to 23.55)-15.11 (-28.15 to -2.06)9.54 (-14.71 to 33.79)
Descending thoracic aorta3.97 (-13.42 to 21.37)2.55 (-12.23 to 17.33)-10.14 (-34.05 to 13.77)1.14 (-26.76 to 29.05)
Carotid bifurcation left2.45 (-1.55 to 6.45)0.64 (-3.59 to 4.88)0.58 (-9.03 to 10.20)2.60 (-2.16 to 7.36)
Carotid bifurcation right-1.64 (-6.02 to 2.74)-0.05 (-3.62 to 3.51)-3.23 (-9.86 to 3.40)1.25 (-3.92 to 6.41)
Common carotid left1.42 (-0.36 to 3.19)1.21 (-1.51 to 3.93)0.65 (-2.82 to 4.13)1.00 (-0.83 to 2.82)
Common carotid right0.02 (-2.54 to 2.58)0.23 (-2.29 to 2.75)-0.80 (-6.25 to 4.64)-1.38 (-3.33 to 0.57)
Internal carotid left5.43 (1.21 to 9.65)3.59 (0.59 to 6.60)1.06 (-2.66 to 4.78)0.33 (-5.07 to 5.73)
Internal carotid right-1.07 (-2.12 to -0.03)0.71 (-1.78 to 3.21)-0.20 (-3.89 to 3.49)0.13 (-2.22 to 2.48)
Descending abdominal aorta10.56 (-8.37 to 29.48)-4.36 (-17.90 to 9.19)12.46 (-46.12 to 71.05)11.82 (-15.26 to 38.90)
SecondaryChange From Baseline in High Sensitivity C-reactive Protein (hsCRP) at Week 4, 12, 24 and 52

High sensitivity C-reactive protein (hsCRP), a soluble biomarker of systemic inflammation was determined in fasting blood samples to evaluate the effect of secukinumab on systemic inflammation.

Time frame:
Baseline, Week 4, 12, 24 and 52
Reported as:
Mean · Milligrams per deciliter (mg/dL)
Change From Baseline in High Sensitivity C-reactive Protein (hsCRP) at Week 4, 12, 24 and 52
Milligrams per deciliter (mg/dL)Secukinumab 300 mgSecukinumab 150 mgPlacebo Followed by 300 mg SecukinumabPlacebo Followed by 150 mg Secukinumab
Week 40.0 (-0.2 to 0.2)-0.2 (-0.4 to -0.1)-0.0 (-0.2 to 0.2)0.1 (-0.1 to 0.3)
Week 12-0.0 (-0.3 to 0.3)-0.2 (-0.3 to 0.0)-0.3 (-0.8 to 0.1)0.1 (-0.4 to 0.6)
Week 24-0.0 (-0.3 to 0.2)-0.0 (-0.3 to 0.2)0.1 (-0.2 to 0.4)-0.4 (-0.9 to 0.1)
Week 52-0.1 (-0.3 to 0.1)-0.2 (-0.4 to -0.0)-0.3 (-0.8 to 0.2)-0.5 (-1.1 to 0.0)
SecondaryChange From Baseline in S-100 Protein B (Total) at Week 4, 12, 24 and 52

S100 calcium-binding protein B (S100B-protein), a soluble biomarker of systemic inflammation was determined in fasting blood samples to evaluate the effect of secukinumab on systemic inflammation.

Time frame:
Baseline, Week 4, 12, 24 and 52
Reported as:
Mean · Microgram per Liter (ug/L)
Change From Baseline in S-100 Protein B (Total) at Week 4, 12, 24 and 52
Microgram per Liter (ug/L)Secukinumab 300 mgSecukinumab 150 mgPlacebo Followed by 300 mg SecukinumabPlacebo Followed by 150 mg Secukinumab
Week 4-0.0 (-0.0 to -0.0)-0.0 (-0.0 to 0.0)0.0 (-0.0 to 0.0)0.0 (-0.0 to 0.0)
Week 12-0.0 (-0.0 to 0.0)-0.0 (-0.0 to 0.0)0.0 (-0.0 to 0.0)0.0 (0.0 to 0.0)
Week 24-0.0 (-0.0 to 0.0)0.0 (-0.0 to 0.0)0.0 (-0.0 to 0.0)0.0 (-0.0 to 0.0)
Week 52-0.0 (-0.0 to 0.0)-0.0 (-0.0 to -0.0)0.0 (-0.0 to 0.0)-0.0 (-0.0 to 0.0)
SecondaryChange From Baseline in Chemokine (C-c Motif) Ligand 5 (CCL5), Monocyte Chemoattractant Protein 1 (MCP-1) and Macrophage Inflammatory Proteins (MIP) 1 Alpha and 1 Beta at Week 4, 12, 24 and 52

Chemokine (c-c motif) ligand 5 (CCL5), Monocyte chemoattractant protein 1 (MCP-1) and Macrophage inflammatory proteins (MIP) 1 alpha (1A) and 1 beta (1B), soluble biomarkers of systemic inflammation were determined in fasting blood samples to evaluate the effect of secukinumab on systemic inflammation.

Time frame:
Baseline, Week 4, 12, 24 and 52
Reported as:
Mean · picograms per milliliter (pg/mL)
Change From Baseline in Chemokine (C-c Motif) Ligand 5 (CCL5), Monocyte Chemoattractant Protein 1 (MCP-1) and Macrophage Inflammatory Proteins (MIP) 1 Alpha and 1 Beta at Week 4, 12, 24 and 52
picograms per milliliter (pg/mL)Secukinumab 300 mgSecukinumab 150 mgPlacebo Followed by 300 mg SecukinumabPlacebo Followed by 150 mg Secukinumab
CCL5 Week 4-1000 (-3106 to 1094)1649 (-597 to 3895)27.0 (-3943 to 3997)-2000 (-5056 to 281.3)
CCL5 Week 122116 (-2368 to 6599)5185 (840.3 to 9530)4393 (-1598 to 10383)3002 (-1806 to 7809)
CCL5 Week 247772 (3766 to 11777)10000 (6437 to 14394)11000 (2117 to 20176)9168 (2124 to 16212)
CCL5 Week 521515 (-2478 to 5507)3577 (-737 to 7891)-597 (-3340 to 2145)2308 (-2558 to 7175)
MCP-1 Week 4-7.0 (-21.8 to 7.7)1.4 (-17.4 to 20.2)-25 (-57.2 to 8.0)17.5 (-43.1 to 78.0)
MCP-1 Week 1218.4 (-1.9 to 38.7)28.6 (-8.4 to 65.7)11.3 (-40.9 to 63.5)21.5 (-18.3 to 61.2)
MCP-1 Week 2439.8 (-0.6 to 80.3)241 (-203 to 685.7)-20 (-53.9 to 14.2)33.4 (8.3 to 58.5)
MCP-1 Week 5222.1 (-18.1 to 62.4)25.4 (-21.7 to 72.6)-11 (-60.6 to 38.6)109 (-13.3 to 230.9)
MIP-1A Week 4-0.1 (-2.1 to 1.9)0.1 (-1.6 to 1.8)0.5 (-2.5 to 3.5)-0.6 (-2.3 to 1.2)
MIP-1A Week 120.2 (-2.8 to 3.3)2.2 (-1.0 to 5.3)-3.6 (-7.0 to -0.3)0.9 (-3.0 to 4.8)
MIP-1A Week 24-0.2 (-2.9 to 2.4)-0.5 (-3.6 to 2.6)-4.7 (-8.4 to -1.0)1.7 (-1.3 to 4.7)
MIP-1A Week 524.3 (-0.1 to 8.7)0.8 (-3.0 to 4.5)1.7 (-6.0 to 9.5)20.1 (4.7 to 35.6)
MIP-1B Week 4-24 (-50.8 to 3.0)-2.6 (-24.8 to 19.5)-16 (-57.5 to 25.8)-20 (-54.4 to 15.3)
MIP-1B Week 12-49 (-80.9 to -16.6)-34 (-69.0 to 1.4)-65 (-106 to -24.7)-68 (-116 to -20.5)
MIP-1B Week 24-52 (-130 to 26.7)-97 (-133 to -61.3)-161 (-207 to -114)79.4 (-261 to 420.3)
MIP-1B Week 52-41 (-73.6 to -8.6)-59 (-89.0 to -29.7)-73 (-122 to -24.2)-31 (-109 to 46.8)
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) at Week 4, 12, 24 and 52

Fasting plasma glucose (FPG), a soluble biomarker of Dysglycemia was determined in fasting blood samples to evaluate the effect of secukinumab on systemic inflammation.

Time frame:
Baseline, Week 4, 12, 24 and 52
Reported as:
Mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 4, 12, 24 and 52
mg/dLSecukinumab 300 mgSecukinumab 150 mgPlacebo Followed by 300 mg SecukinumabPlacebo Followed by 150 mg Secukinumab
Week 41.5 (-1.0 to 4.0)-1.6 (-4.6 to 1.3)0.9 (-4.4 to 6.1)0.2 (-5.2 to 5.6)
Week 123.5 (-0.0 to 7.0)1.1 (-4.0 to 6.2)5.3 (-2.2 to 12.8)-1.5 (-7.1 to 4.0)
Week 242.5 (0.0 to 5.0)1.4 (-6.3 to 9.1)12.1 (-10.8 to 35.0)-1.4 (-7.7 to 5.0)
Week 52-0.8 (-3.5 to 2.0)0.7 (-3.0 to 4.4)8.7 (-7.5 to 25.0)0.9 (-6.7 to 8.6)
SecondaryChange From Baseline in Fasting Insulin at Week 4, 12, 24 and 52

Fasting Insulin, a soluble biomarker of Dysglycemia was determined in fasting blood samples to evaluate the effect of secukinumab on Dysglycemia.

Time frame:
Baseline, Week 4, 12, 24 and 52
Reported as:
Mean · micro units per millilitre (uU/mL)
Change From Baseline in Fasting Insulin at Week 4, 12, 24 and 52
micro units per millilitre (uU/mL)Secukinumab 300 mgSecukinumab 150 mgPlacebo Followed by 300 mg SecukinumabPlacebo Followed by 150 mg Secukinumab
Week 40.4 (-2.0 to 2.7)0.4 (-2.3 to 3.0)-4.7 (-17.4 to 8.1)-0.5 (-4.8 to 3.7)
Week 12-1.4 (-5.1 to 2.4)1.1 (-2.7 to 4.8)-2.2 (-9.2 to 4.7)-0.1 (-4.9 to 4.7)
Week 24-1.0 (-4.1 to 2.0)0.5 (-3.7 to 4.8)-5.3 (-18.5 to 8.0)-2.0 (-6.1 to 2.0)
Week 52-0.4 (-4.3 to 3.6)1.5 (-1.3 to 4.2)-1.2 (-7.5 to 5.1)3.0 (-5.2 to 11.3)
SecondaryChange From Baseline in Homeostatic Model Assessment (HOMA) Beta-cell Function at Week 4, 12, 24 and 52

Homeostatic Model Assessment (HOMA) beta-cell function, a soluble biomarker of Dysglycemia was determined in fasting blood samples to evaluate the effect of secukinumab on Dysglycemia.

Time frame:
Baseline, Week 4, 12, 24 and 52
Reported as:
Mean · Percentage
Change From Baseline in Homeostatic Model Assessment (HOMA) Beta-cell Function at Week 4, 12, 24 and 52
PercentageSecukinumab 300 mgSecukinumab 150 mgPlacebo Followed by 300 mg SecukinumabPlacebo Followed by 150 mg Secukinumab
Week 4-18 (-64.7 to 28.2)-0.2 (-25.7 to 25.3)-28 (-88.4 to 33.0)-8.9 (-38.5 to 20.7)
Week 12-16 (-74.4 to 41.5)3.9 (-32.0 to 39.8)-29 (-100 to 41.6)16.6 (-20.6 to 53.8)
Week 24-25 (-53.9 to 3.5)-8.2 (-40.2 to 23.9)-35 (-111 to 40.7)-26 (-63.2 to 12.0)
Week 5211.5 (-40.5 to 63.5)-1.6 (-32.6 to 29.4)9.3 (-56.4 to 75.1)11.6 (-26.6 to 49.7)
SecondaryChange From Baseline in Homeostatic Model Assessment (HOMA) Insulin Resistance at Week 4, 12, 24 and 52

HOMA insulin resistance, a soluble biomarker of Dysglycemia was determined in fasting blood samples to evaluate the effect of secukinumab on Dysglycemia.

Time frame:
Baseline, Week 4, 12, 24 and 52
Reported as:
Mean · Insulin Resistance Index
Change From Baseline in Homeostatic Model Assessment (HOMA) Insulin Resistance at Week 4, 12, 24 and 52
Insulin Resistance IndexSecukinumab 300 mgSecukinumab 150 mgPlacebo Followed by 300 mg SecukinumabPlacebo Followed by 150 mg Secukinumab
Week 40.3 (-0.6 to 1.2)0.1 (-0.9 to 1.0)-1.1 (-5.2 to 3.1)-0.3 (-2.0 to 1.3)
Week 12-0.1 (-1.5 to 1.4)0.6 (-0.7 to 1.8)-0.1 (-2.5 to 2.3)-0.4 (-2.0 to 1.3)
Week 24-0.3 (-1.1 to 0.6)0.6 (-1.3 to 2.5)-1.1 (-5.0 to 2.8)-0.7 (-2.2 to 0.8)
Week 52-0.2 (-1.2 to 0.9)0.6 (-0.3 to 1.4)-0.2 (-2.8 to 2.4)0.7 (-1.9 to 3.4)
SecondaryChange From Baseline in Hemoglobin A1c (Glycated Hemoglobin) at Week 4, 12, 24 and 52

Hemoglobin A1c (glycated hemoglobin), a soluble biomarker of Dysglycemia was determined in fasting blood samples to evaluate the effect of secukinumab on Dysglycemia.

Time frame:
Baseline, Week 4, 12, 24 and 52
Reported as:
Mean · millimole per mole of Haemoglobin
Change From Baseline in Hemoglobin A1c (Glycated Hemoglobin) at Week 4, 12, 24 and 52
millimole per mole of HaemoglobinSecukinumab 300 mgSecukinumab 150 mgPlacebo Followed by 300 mg SecukinumabPlacebo Followed by 150 mg Secukinumab
Week 40.2 (-0.5 to 0.8)-0.4 (-1.0 to 0.3)-0.7 (-2.3 to 1.0)-0.4 (-1.2 to 0.4)
Week 120.4 (-0.7 to 1.5)-0.4 (-2.2 to 1.4)-1.2 (-3.8 to 1.3)0.1 (-0.8 to 1.0)
Week 24-0.4 (-1.7 to 1.0)-1.2 (-2.9 to 0.5)-0.1 (-2.4 to 2.1)-1.2 (-2.9 to 0.6)
Week 52-1.1 (-2.3 to 0.1)-2.8 (-6.1 to 0.4)-1.9 (-4.3 to 0.6)-2.1 (-3.0 to 1.2)
SecondaryChange From Baseline in Sex Hormone-binding Globulin (SHBG) at Week 4, 12, 24 and 52

Sex hormone-binding globulin (SHBG), a soluble biomarker of Dysglycemia was determined in fasting blood samples to evaluate the effect of secukinumab on Dysglycemia.

Time frame:
Baseline, Week 4, 12, 24 and 52
Reported as:
Mean · nanomole per Liter (nmol/L)
Change From Baseline in Sex Hormone-binding Globulin (SHBG) at Week 4, 12, 24 and 52
nanomole per Liter (nmol/L)Secukinumab 300 mgSecukinumab 150 mgPlacebo Followed by 300 mg SecukinumabPlacebo Followed by 150 mg Secukinumab
Week 40.1 (-1.8 to 2.1)3.7 (-3.0 to 10.4)4.7 (-4.2 to 13.5)-0.3 (-4.0 to 3.5)
Week 12-0.1 (-3.4 to 3.2)1.1 (-1.8 to 4.1)3.7 (-1.6 to 9.1)4.1 (-0.2 to 8.4)
Week 24-1.5 (-5.1 to 2.2)3.2 (-0.9 to 7.2)1.7 (-2.9 to 6.3)2.6 (-1.5 to 6.7)
Week 52-3.1 (-10.8 to 4.6)5.9 (-1.3 to 13.0)-2.6 (-14.9 to 9.6)3.2 (-4.3 to 10.8)
SecondaryChange From Baseline in Triglycerides, Total Cholesterol, Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), Apolipoprotein A-1 (ApoA-1) and Apolipoprotein B (ApoB) at Week 4, 12, 24 and 52

Triglycerides, Total cholesterol, Low density lipoprotein (LDL), High density lipoprotein (HDL), Apolipoprotein A-1 (ApoA-1) and Apolipoprotein B (ApoB), soluble biomarkers of impaired lipid metabolism were determined in fasting blood samples to evaluate the effect of secukinumab on impaired lipid metabolism.

Time frame:
Baseline, Week 4, 12, 24 and 52
Reported as:
Mean · mg/dL
Change From Baseline in Triglycerides, Total Cholesterol, Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), Apolipoprotein A-1 (ApoA-1) and Apolipoprotein B (ApoB) at Week 4, 12, 24 and 52
mg/dLSecukinumab 300 mgSecukinumab 150 mgPlacebo Followed by 300 mg SecukinumabPlacebo Followed by 150 mg Secukinumab
Triglycerides Week 4-1.8 (-15.5 to 12.0)6.5 (-5.9 to 18.9)12.7 (-12.2 to 37.7)27.5 (-6.6 to 61.6)
Triglycerides Week 12-9.3 (-20.8 to 2.3)4.0 (-9.3 to 17.3)5.9 (-32.4 to 44.2)2.7 (-18.3 to 23.8)
Triglycerides Week 244.6 (-16.6 to 25.8)3.9 (-9.1 to 16.9)32.8 (-19.7 to 85.2)17.1 (-2.3 to 36.5)
Triglycerides Week 5264.6 (-44.0 to 173.2)2.6 (-11.7 to 16.9)-6.0 (-54.3 to 42.3)11.9 (-8.6 to 32.3)
Total cholesterol Week 40.4 (-6.4 to 7.1)7.1 (1.1 to 13.2)4.8 (-3.2 to 12.8)-2.7 (-10.0 to 4.7)
Total cholesterol Week 123.1 (-3.1 to 9.4)3.6 (-4.1 to 11.2)10.0 (2.8 to 17.1)-4.2 (-11.2 to 2.8)
Total cholesterol Week 240.9 (-5.2 to 7.1)0.6 (-4.9 to 6.1)7.2 (-1.5 to 16.0)-3.2 (-12.0 to 5.5)
Total cholesterol Week 527.8 (0.0 to 15.6)2.3 (-5.2 to 9.9)8.9 (2.1 to 15.7)2.9 (-5.9 to 11.7)
LDL Week 41.1 (-4.6 to 6.8)6.8 (0.8 to 12.8)5.2 (-2.0 to 12.4)-5.6 (-12.1 to 0.8)
LDL Week 122.9 (-2.2 to 7.9)2.7 (-4.8 to 10.1)9.5 (3.4 to 15.5)-5.6 (-12.7 to 1.5)
LDL Week 24-2.7 (-8.1 to 2.7)-1.3 (-6.9 to 4.4)1.1 (-7.4 to 9.5)-11 (-18.9 to -2.4)
LDL Week 521.7 (-6.5 to 9.9)-0.9 (-8.4 to 6.5)8.2 (1.3 to 15.0)1.1 (-8.4 to 10.5)
HDL Week 4-0.6 (-2.6 to 1.3)0.4 (-1.5 to 2.2)0.3 (-2.3 to 2.9)-1.3 (-4.6 to 2.0)
HDL Week 12-0.4 (-2.4 to 1.6)0.2 (-1.8 to 2.2)1.0 (-1.2 to 3.3)-0.5 (-4.9 to 3.8)
HDL Week 241.2 (-1.5 to 3.9)0.3 (-2.3 to 2.8)-1.1 (-3.4 to 1.3)0.5 (-4.1 to 5.1)
HDL Week 520.1 (-2.1 to 2.4)1.8 (-0.5 to 4.2)-0.3 (-2.9 to 2.4)-1.4 (-4.6 to 1.8)
ApoA-1 Week 40.3 (-5.1 to 5.7)0.9 (-4.0 to 5.7)7.7 (-0.6 to 15.9)-5.5 (-12.0 to 1.0)
ApoA-1 Week 124.0 (-2.0 to 10.1)2.4 (-1.9 to 6.8)7.1 (1.2 to 12.9)-3.3 (-12.1 to 5.5)
ApoA-1 Week 245.5 (-0.9 to 12.0)2.8 (-3.0 to 8.6)3.0 (-3.3 to 9.3)-3.1 (-11.3 to 5.1)
ApoA-1 Week 52-4.5 (-10.0 to 0.9)-6.0 (-11.6 to -0.3)-5.5 (-14.9 to 3.9)-13 (-22.3 to -3.1)
ApoB Week 41.5 (-2.7 to 5.6)3.6 (0.5 to 6.6)2.7 (-1.1 to 6.5)-2.5 (-7.7 to 2.8)
ApoB Week 124.0 (0.6 to 7.4)3.4 (-0.5 to 7.3)7.4 (3.9 to 11.0)-1.0 (-7.0 to 4.9)
ApoB Week 241.0 (-2.8 to 4.8)2.0 (-1.3 to 5.3)5.6 (1.4 to 9.9)-4.2 (-10.7 to 2.3)
ApoB Week 523.7 (-2.2 to 9.6)2.3 (-1.8 to 6.4)6.7 (3.0 to 10.5)-0.2 (-5.4 to 5.0)
SecondaryChange From Baseline in Adiponectin at Week 4, 12, 24 and 52

Adiponectin, a soluble biomarker of impaired lipid metabolism was determined in fasting blood samples to evaluate the effect of secukinumab on systemic inflammation.

Time frame:
Baseline, Week 4, 12, 24 and 52
Reported as:
Mean · ug/mL
Change From Baseline in Adiponectin at Week 4, 12, 24 and 52
ug/mLSecukinumab 300 mgSecukinumab 150 mgPlacebo Followed by 300 mg SecukinumabPlacebo Followed by 150 mg Secukinumab
Week 4-0.5 (-1.0 to -0.1)0.2 (-0.4 to 0.8)-0.1 (-0.8 to 0.5)-0.6 (-1.2 to -0.0)
Week 12-0.5 (-1.1 to -0.0)-0.2 (-0.7 to 0.3)0.5 (0.1 to 0.9)0.3 (-0.7 to 1.3)
Week 240.3 (-0.3 to 0.9)0.1 (-0.5 to 0.7)0.7 (-0.3 to 1.8)-0.6 (-1.6 to 0.3)
Week 52-1.1 (-1.6 to -0.6)-0.9 (-1.5 to -0.3)-0.4 (-1.0 to 0.2)-1.1 (-2.0 to -0.3)
SecondaryChange From Baseline in Leptin at Week 4, 12, 24 and 52

Leptin, a soluble biomarker of impaired lipid metabolism was determined in fasting blood samples to evaluate the effect of secukinumab on systemic inflammation.

Time frame:
Baseline, Week 4, 12, 24 and 52
Reported as:
Mean · ng/mL (nanogram per milliliter)
Change From Baseline in Leptin at Week 4, 12, 24 and 52
ng/mL (nanogram per milliliter)Secukinumab 300 mgSecukinumab 150 mgPlacebo Followed by 300 mg SecukinumabPlacebo Followed by 150 mg Secukinumab
Week 4-0.6 (-1.8 to 0.7)1.0 (-0.1 to 2.2)-0.2 (-1.6 to 1.2)0.3 (-1.2 to 1.9)
Week 120.2 (-0.7 to 1.1)0.1 (-0.9 to 1.2)0.7 (-1.0 to 2.4)-0.3 (-1.7 to 1.2)
Week 240.2 (-0.7 to 1.2)1.0 (-0.5 to 2.4)-0.3 (-2.8 to 2.3)-1.4 (-4.9 to 2.1)
Week 520.2 (-1.0 to 1.3)-0.5 (-1.6 to 0.7)-0.4 (-3.8 to 3.0)-2.9 (-5.7 to 0.0)

Adverse events

Collected over From signing of Informed Consent up to 30 days post last drug treatment.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Secukinumab (300 mg) up to Week 12—1/48 (2.1%)29/48 (60.4%)
Secukinumab (150 mg) up to Week 12—0/54 (0%)36/54 (66.7%)
Placebo up to Week 12—2/49 (4.1%)35/49 (71.4%)
Secukinumab (300 mg) After Week 12—6/48 (12.5%)36/48 (75%)
Secukinumab (150 mg) After Week 12—6/54 (11.1%)43/54 (79.6%)
Placebo Followed by Secukinumab (300 mg) After Week 12—0/26 (0%)21/26 (80.8%)
Placebo Followed by Secukinumab (150 mg) After Week 12—1/23 (4.3%)19/23 (82.6%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventSecukinumab (300 mg) up to Week 12Secukinumab (150 mg) up to Week 12Placebo up to Week 12Secukinumab (300 mg) After Week 12Secukinumab (150 mg) After Week 12Placebo Followed by Secukinumab (300 mg) After Week 12Placebo Followed by Secukinumab (150 mg) After Week 12
RHEUMATOID ARTHRITISMusculoskeletal and connective tissue disorders0/480/540/490/480/540/261/23
VESTIBULAR DISORDEREar and labyrinth disorders0/480/540/491/480/540/260/23
DUODENAL ULCERGastrointestinal disorders0/480/540/491/480/540/260/23
GASTRIC ULCERGastrointestinal disorders0/480/540/491/480/540/260/23
GASTRITIS EROSIVEGastrointestinal disorders0/480/540/491/480/540/260/23
ANAL ABSCESSInfections and infestations0/480/540/491/480/540/260/23
ERYSIPELASInfections and infestations0/480/540/491/480/540/260/23
HELICOBACTER INFECTIONInfections and infestations0/480/540/491/480/540/260/23
PNEUMONIA BACTERIALInfections and infestations1/480/540/490/480/540/260/23
JOINT DISLOCATIONInjury, poisoning and procedural complications0/480/540/491/480/540/260/23
Most frequent other events
Showing 10 of 88
Most frequent other events
EventSecukinumab (300 mg) up to Week 12Secukinumab (150 mg) up to Week 12Placebo up to Week 12Secukinumab (300 mg) After Week 12Secukinumab (150 mg) After Week 12Placebo Followed by Secukinumab (300 mg) After Week 12Placebo Followed by Secukinumab (150 mg) After Week 12
NASOPHARYNGITISInfections and infestations10/4814/5418/4921/4825/5410/2610/23
BACK PAINMusculoskeletal and connective tissue disorders2/482/541/494/484/545/261/23
RHINITISInfections and infestations1/480/542/492/483/541/264/23
HEADACHENervous system disorders4/486/542/497/487/542/260/23
ARTHRALGIAMusculoskeletal and connective tissue disorders1/482/545/495/483/540/263/23
DIARRHOEAGastrointestinal disorders2/482/541/490/483/543/261/23
CONJUNCTIVITISInfections and infestations0/480/540/490/481/542/260/23
HAEMATURIARenal and urinary disorders2/482/540/491/480/542/260/23
RHINITIS ALLERGICRespiratory, thoracic and mediastinal disorders0/481/540/490/480/542/260/23
COUGHRespiratory, thoracic and mediastinal disorders2/480/543/492/484/541/260/23

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Secukinumab 300 mgSecukinumab 150 mgPlacebo Followed by 300 mg SecukinumabPlacebo Followed by 150 mg SecukinumabTotal
<=18 years00000
Between 18 and 65 years46462622140
>=65 years280111
Age, Continuous
Age, Continuous(years)Secukinumab 300 mgSecukinumab 150 mgPlacebo Followed by 300 mg SecukinumabPlacebo Followed by 150 mg SecukinumabTotal
Mean44.2 ± 12.946.0 ± 14.443.7 ± 11.446.8 ± 13.145.2 ± 13.2
Sex: Female, Male
Sex: Female, Male(Participants)Secukinumab 300 mgSecukinumab 150 mgPlacebo Followed by 300 mg SecukinumabPlacebo Followed by 150 mg SecukinumabTotal
Female11238749
Male37311816102
Region of Enrollment
Region of Enrollment(participants)Secukinumab 300 mgSecukinumab 150 mgPlacebo Followed by 300 mg SecukinumabPlacebo Followed by 150 mg SecukinumabTotal
Germany48542623151
08

Study locations

23 sites
  • Novartis Investigative Site
    Augsburg, 86179, Germany
  • Novartis Investigative Site
    Berlin, 10789, Germany
  • Novartis Investigative Site
    Berlin, 13187, Germany
  • Novartis Investigative Site
    Bielefeld, 33647, Germany
  • Novartis Investigative Site
    Bochum, 44791, Germany
  • Novartis Investigative Site
    Bonn, 53105, Germany
  • Novartis Investigative Site
    Darmstadt, 64283, Germany
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Duisburg, 47166, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Frankfurt, 60590, Germany
  • Novartis Investigative Site
    Freiburg, 79104, Germany
  • Novartis Investigative Site
    Gera, 07548, Germany
  • Novartis Investigative Site
    Hamburg, 20354, Germany
  • Novartis Investigative Site
    Heidelberg, 69120, Germany
  • Novartis Investigative Site
    Homburg, 66421, Germany
  • Novartis Investigative Site
    Langenau, 89129, Germany
  • Novartis Investigative Site
    Lubeck, 23538, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    Muenster, 48149, Germany
  • Novartis Investigative Site
    München, 81675, Germany
  • Novartis Investigative Site
    Stade, 21682, Germany
  • Novartis Investigative Site
    Ulm, 89081, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of Apr 2016 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2017, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2015
First posted
Sep 24, 2015
Start
Apr 2014
Primary completionActual
Apr 2016
CompletionActual
Apr 2016
Results first posted
Jul 13, 2017
Last update
Jul 13, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02559622
Responsible party
Sponsor
First posted
Sep 24, 2015
Start date
Apr 2014
Primary completion
Apr 2016
Completion
Apr 2016
Results posted
Jul 13, 2017
Last update
Jul 13, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion